Systemic sclerosis myocarditis has unique clinical, histological and prognostic features: a comparative histological analysis.

OBJECTIVE To outline the clinical, histological and prognostic features of systemic sclerosis (SSc) endomyocardial biopsy-proven myocarditis with respect to those of diverse endomyocardial biopsy-proven virus-negative myocarditis (VNM). METHODS We retrospectively analysed data from three cohorts of endomyocardial biopsy-proven myocarditis: SSc-related VNM (SSc-VNM); isolated VNM (i-VNM); and VNM related to other systemic autoimmune diseases (a-VNM). The degree of myocardial fibrosis was expressed as relative percentage and fibrotic score (0-3). Clinical data, cardiac enzymes, echocardiogram, 24 h ECG Holter and cardiac magnetic resonance were obtained at baseline and during follow-up. Non-parametric tests were used. RESULTS We enrolled 12 SSc-VNM [11 females, mean age 49.3 (14.2) years; seven diffuse-SSc, five early-SSc], 12 i-VNM [12 females, mean age 47.7 (10.8) years] and 10 a-VNM [four females, mean age 48.4 (16.3) years] patients. SSc patients had higher degrees of myocardial fibrosis as assessed by both percentage [SSc-VNM: 44.8 (18.8)%; a-VNM: 28.6 (16.5)%; i-VNM: 24.9 (10.3)%; P = 0.019] and score [SSc-VNM: 2.3 (0.8); a-VNM: 1.4 (1.1); i-VNM: 1.2 (0.7); P = 0.002]. Myocardial fibrosis directly correlated with skin score (r = 0.625, P = 0.03) and number of ventricular ectopic beats on 24 h ECG Holter in SSc patients (r = 0.756, P = 0.01). Dyspnoea class was higher at presentation in SSc-VNM patients (P = 0.041) and we found heart failure only in SSc patients (25%) (P = 0.05). At cardiac magnetic resonance, myocardial oedema was nearly undetectable in SSc-VNM patients compared with others (P = 0.02). All patients received immunosuppressive treatment. The number of patients who died during follow-up due to cardiac complications was significantly higher in SSc-VNM patients (50%), as compared with a-VNM (0%) and i-VNM (8.3%) patients (P = 0.006). Patients who died during follow-up had higher degrees of myocardial fibrosis [52.2 (11.6)% vs 27.5 (12.9)%, P = 0.024; fibrotic score: 2.83 (0.41) vs 1.4 (0.9), P < 0.001]. CONCLUSION SSc has unique clinical and histological features, as it tends to present more frequently with heart failure and a higher dyspnoea class and to show higher degrees of myocardial fibrosis. These specific features are paralleled by a worse cardiac prognosis.

[1]  C. Campochiaro,et al.  Anti-Ku syndrome with elevated CK: association with myocardial involvement in systemic sclerosis , 2019, Annals of the Rheumatic Diseases.

[2]  H. Dalen,et al.  Systolic Dysfunction in Systemic Sclerosis: Prevalence and Prognostic Implications , 2019, ACR open rheumatology.

[3]  M. Nurmohamed,et al.  Microvascular heart involvement in systemic autoimmune diseases: The purinergic pathway and therapeutic insights from the biology of the diseases. , 2019, Autoimmunity reviews.

[4]  S. Rizzo,et al.  Impact of systemic immune-mediated diseases on clinical features and prognosis of patients with biopsy-proved myocarditis. , 2019, International journal of cardiology.

[5]  G. Thiene,et al.  Successful use of sirolimus in a patient with cardiac microangiopathy in primary antiphospholipid syndrome , 2019, Scandinavian journal of rheumatology.

[6]  G. de Luca,et al.  Cardiac troponin T and NT-proBNP as diagnostic and prognostic biomarkers of primary cardiac involvement and disease severity in systemic sclerosis: A prospective study. , 2019, European journal of internal medicine.

[7]  C. Campochiaro,et al.  Unexpected acute lymphocytic virus-negative myocarditis in a patient with limited cutaneous systemic sclerosis: a case report , 2018, Scandinavian journal of rheumatology.

[8]  S. Rizzo,et al.  Efficacy and safety of mycophenolate mofetil in patients with virus-negative lymphocytic myocarditis: A prospective cohort study. , 2019, Journal of autoimmunity.

[9]  A. Tomelleri,et al.  Efficacy and Safety of Methotrexate for the Treatment of Autoimmune Virus-Negative Myocarditis: A Case Series. , 2018, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[10]  C. Campochiaro,et al.  Treatment of Dilated Cardiomyopathy With Interleukin-1 Inhibition. , 2018, Annals of internal medicine.

[11]  C. Campochiaro,et al.  Myocarditis: An Interleukin-1-Mediated Disease? , 2018, Front. Immunol..

[12]  A. Tomelleri,et al.  Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim–Chester Disease , 2018, Front. Immunol..

[13]  D. Gladman,et al.  Lupus myocarditis: a single center experience and a comparative analysis of observational cohort studies , 2018, Lupus.

[14]  J. Lima,et al.  Cardiac magnetic resonance imaging in myocardial inflammation in autoimmune rheumatic diseases: An appraisal of the diagnostic strengths and limitations of the Lake Louise criteria. , 2018, International journal of cardiology.

[15]  F. Crea,et al.  Life-threatening arrhythmias in a scleroderma patient: the role of myocardial inflammation in arrhythmic outburst , 2017, Scandinavian journal of rheumatology.

[16]  F. Crea,et al.  Prognostic Role of Ventricular Ectopic Beats in Systemic Sclerosis: A Prospective Cohort Study Shows ECG Indexes Predicting the Worse Outcome , 2016, PloS one.

[17]  Andrea Mazzanti,et al.  2015 ESC Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. , 2016, Revista espanola de cardiologia.

[18]  G. Lippi,et al.  Troponin in Stable Ischemic Heart Disease and Diabetes. , 2015, The New England journal of medicine.

[19]  P. Cluzel,et al.  Myocarditis in Patients With Antisynthetase Syndrome , 2015, Medicine.

[20]  U. Kramer,et al.  Clinical and Histopathological Features of Patients with Systemic Sclerosis Undergoing Endomyocardial Biopsy , 2015, PloS one.

[21]  P. Matthews,et al.  Diffuse Myocardial Fibrosis and Inflammation in Rheumatoid Arthritis: Insights From CMR T1 Mapping. , 2015, JACC. Cardiovascular imaging.

[22]  Zhilin Qu,et al.  Cardiac fibrosis and arrhythmogenesis: the road to repair is paved with perils. , 2014, Journal of molecular and cellular cardiology.

[23]  F. Crea,et al.  Recognizing and treating myocarditis in recent-onset systemic sclerosis heart disease: potential utility of immunosuppressive therapy in cardiac damage progression. , 2014, Seminars in arthritis and rheumatism.

[24]  S. Kaptoge,et al.  Meta-analysis of ventricular premature complexes and their relation to cardiac mortality in general populations. , 2013, The American journal of cardiology.

[25]  Stefan Neubauer,et al.  T(1) mapping for the diagnosis of acute myocarditis using CMR: comparison to T2-weighted and late gadolinium enhanced imaging. , 2013, JACC. Cardiovascular imaging.

[26]  A. Angelini,et al.  Classification and histological, immunohistochemical, and molecular diagnosis of inflammatory myocardial disease , 2013, Heart Failure Reviews.

[27]  A. Angelini,et al.  2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. , 2012, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[28]  P. MacEneaney,et al.  Successful control of scleroderma myocarditis using a combination of cyclophosphamide and methylprednisolone , 2010, Scandinavian journal of rheumatology.

[29]  E. Feierl,et al.  Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database , 2010, Annals of the rheumatic diseases.

[30]  D. Farge,et al.  Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis , 2009, Annals of the rheumatic diseases.

[31]  G. Kolovou,et al.  Myocardial inflammation in autoimmune diseases: investigation by cardiovascular magnetic resonance and endomyocardial biopsy. , 2009, Inflammation & allergy drug targets.

[32]  Andrea Frustaci,et al.  Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. , 2009, European heart journal.

[33]  Matthias Gutberlet,et al.  Cardiovascular Magnetic Resonance in Myocarditis: A JACC White Paper , 2009 .

[34]  D. Corrado,et al.  Quantitative assessment of endomyocardial biopsy in arrhythmogenic right ventricular cardiomyopathy/dysplasia: an in vitro validation of diagnostic criteria. , 2008, European heart journal.

[35]  H. Champion The heart in scleroderma. , 2008, Rheumatic diseases clinics of North America.

[36]  J. Ornato,et al.  [ACC/AHA/ESC 2006 guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary]. , 2006, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.

[37]  Dan M. Roden,et al.  ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines , 2006 .

[38]  K. Resch,et al.  Fasting followed by vegetarian diet in patients with rheumatoid arthritis: a systematic review. , 2001, Scandinavian journal of rheumatology.

[39]  B. Boland,et al.  Intravascular haemolysis in hypertrophic cardiomyopathy. , 1996, European heart journal.

[40]  B Maisch,et al.  Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. , 1996, Circulation.

[41]  W. Edwards,et al.  Myocarditis. A histopathologic definition and classification. , 1987, The American journal of cardiovascular pathology.

[42]  G. Hutchins,et al.  Myocardial Lesions of Progressive Systemic Sclerosis: A Cause of Cardiac Dysfunction , 1976, Circulation.

[43]  E. F. Doyle,et al.  Major Changes Made by Criteria Committee of the New York Heart Association , 1974, Circulation.